

# Lonidamine

Catalog No: tcsc2602



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

50264-69-2

**Formula:**

$C_{15}H_{10}Cl_2N_2O_2$

**Pathway:**

Metabolic Enzyme/Protease

**Target:**

Hexokinase

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

DICA;Diclondazolic Acid;AF1890

**Observed Molecular Weight:**


321.16

## Product Description

Lonidamine is an orally administered small molecule hexokinase inactivator.

Target: Others

Lonidamine is a derivative of indazole-3-carboxylic acid, which for a long time, has been known to inhibit aerobic glycolysis in cancer cells. It seems to enhance aerobic glycolysis in normal cells, but suppress glycolysis in cancer cells. This is most likely through the inhibition of the mitochondrially bound hexokinase. Later studies in Ehrlich ascites tumor cells showed that lonidamine inhibits both respiration and glycolysis leading to a decrease in cellular ATP. Clinical trials of lonidamine in combination with other anticancer agents for a variety of cancers has begun. Lonidamine has been used in the treatment of brain tumours in combination with radiotherapy and temozolomide. Results showed that a combination of temozolomide and lonidamine at clinically achievable, low plasma concentrations, could inhibit tumour growth, and lonidamine could reduce the dose of temozolomide required for radiosensitization of brain tumours. From Wikipedia.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!